Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study.

Date publication

février 2025

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr D'AVENI-PINEY Maud

Tous les auteurs :
Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A, Hellström-Lindberg E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39909656

Résumé

In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects on survival and health-related quality of life (HRQoL) of exposure to ESAs with or without RBCT in patients with lower risk myelodysplastic syndromes.

Mots clés

Humans, Quality of Life, Myelodysplastic Syndromes, drug therapy, Female, Male, Hematinics, therapeutic use, Aged, Middle Aged, Erythrocyte Transfusion, adverse effects, Registries, Aged, 80 and over, Cohort Studies, Longitudinal Studies

Référence

Lancet Haematol. 2025 02;12(2):e128-e137